Company intelligence / Profile preview
IM Therapeutics
Boston, Massachusetts, United Statesimtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
IM Therapeutics has developed a personalized oral small molecule therapy targeting the HLA-DQ8 protein to prevent immune-mediated destruction of insulin-producing beta cells in type 1 diabetes. Their lead candidate, IMT‑002 (D-methyldopa), has received Orphan Drug Status from the FDA and entered Phase I clinical trials in mid‑2020. The company’s approach aims to address high unmet needs in T1D and celiac disease by blocking key genetic drivers of autoimmunity. Initial results focus on safety and pharmacodynamics; further data pending.
- Therapeutic areas
- GastroenterologyEndocrinologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on IM Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM Therapeutics.